US Bank Regulators Clarify Capital Rules for Tokenized Securities
WASHINGTON – Federal banking regulators have issued guidance clarifying how banks should treat tokenized securities under existing capital rules. The agencies affirmed that eligible tokenized securities should generally receive the same capital treatment as their non-tokenized counterparts, reinforcing a technology-neutral approach to financial regulation.
What are Tokenized Securities?
A tokenized security is a digital representation of a traditional financial instrument, with ownership recorded using distributed ledger technology (DLT), often referred to as blockchain. Instead of traditional recordkeeping systems, ownership rights are recorded and transferred through DLT.
Key Findings from the Regulatory Guidance
The Federal Reserve, Federal Deposit Insurance Corporation (FDIC), and Office of the Comptroller of the Currency (OCC) jointly released answers to frequently asked questions (FAQs) on March 5, 2026, to address uncertainty surrounding capital requirements for blockchain-based securities. The core principle outlined in the guidance is that the capital rule is “technology neutral.”
- Technology Neutrality: The agencies emphasized that the regulatory framework is designed to remain neutral with respect to technology.
- No Impact from Issuance or Transaction Methods: The methods used to issue or transact in a security generally do not impact its capital treatment.
- Blockchain Type Irrelevant: The guidance does not differentiate between securities issued on permissioned blockchains and those operating on permissionless networks.
Implications for Banks
This clarification aims to reduce uncertainty for banks considering engaging with tokenized securities. Banks holding tokenized securities are still required to apply sound risk management practices and comply with all applicable laws and regulations.
Further Information
The complete FAQs document is available from the OCC: Capital Treatment of Tokenized Securities FAQs
Keep reading
- How GLP-1 Medications Affect the Brain
- Hospital COVID-19 Protocols: Remdesivir and Ventilator Deaths Examined
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)